Published in Breast Cancer Res Treat on February 24, 2012
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer (2013) 1.10
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat (2013) 0.97
Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics (2014) 0.96
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. Genet Med (2014) 0.82
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer (2012) 0.81
Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer. J Clin Oncol (2015) 0.79
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use? Breast Cancer Res Treat (2012) 0.76
Genome-based risk prediction for early stage breast cancer. Oncologist (2014) 0.75
Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol (2017) 0.75
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Considerations and costs of disclosing study findings to research participants. CMAJ (2004) 1.97
Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med (2006) 1.60
Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. CMAJ (2007) 1.42
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev (2012) 1.21
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer (2008) 1.19
Interfaces across the cancer continuum offer opportunities to improve the process of care. J Natl Cancer Inst Monogr (2010) 1.18
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat (2008) 1.17
Eliminating the shortage of registered nurses in Canada: an exercise in applied needs-based planning. Health Policy (2011) 1.10
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Long-run consequences of parental paid work hours for child overweight status in Canada. Soc Sci Med (2005) 1.10
Planning for what? Challenging the assumptions of health human resources planning. Health Policy (2009) 1.07
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev (2008) 1.04
The coordination of primary and oncology specialty care at the end of life. J Natl Cancer Inst Monogr (2010) 1.01
Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol (2008) 0.98
Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol (2008) 0.97
Simultaneous liver kidney transplantation: a medical decision analysis. Transplantation (2011) 0.96
Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med (2011) 0.96
An incremental cost analysis of telehealth in Nova Scotia from a societal perspective. J Telemed Telecare (2005) 0.95
Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. Clin Breast Cancer (2011) 0.95
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer (2011) 0.94
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat (2014) 0.92
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer (2012) 0.92
Cross-district utilization of general hospital care in Nova Scotia: policy and service delivery implications for rural districts. Soc Sci Med (2005) 0.92
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat (2007) 0.91
Improving nodal harvest in colorectal cancer: so what? Ann Surg Oncol (2011) 0.86
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol (2009) 0.85
Gout in the elderly--a population health study. J Rheumatol (2009) 0.85
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health (2011) 0.85
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol (2014) 0.85
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat (2007) 0.84
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res (2002) 0.83
Flat epithelial atypia on breast needle core biopsy: a retrospective study with clinical-pathological correlation. Breast J (2010) 0.82
Survivin and COX-2 expression in male breast carcinoma. Breast (2009) 0.82
Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev Pharmacoecon Outcomes Res (2008) 0.82
The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat (2006) 0.81
Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer? Expert Rev Pharmacoecon Outcomes Res (2013) 0.81
Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care. Healthc Policy (2011) 0.81
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact. Breast J (2014) 0.81
Effect of copayments on drug use in the presence of annual payment limits. Am J Manag Care (2007) 0.80
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat (2007) 0.80
How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study. Implement Sci (2012) 0.79
Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology (2011) 0.79
Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. Int J Pharm Pract (2013) 0.79
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist (2013) 0.78
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clin Med Insights Oncol (2012) 0.78
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial. Support Care Cancer (2011) 0.78
Gendered and cultured relations: exploring African Nova Scotians' perceptions and experiences of breast and prostate cancer. Res Theory Nurs Pract (2005) 0.78
Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Am J Clin Oncol (2013) 0.76
Hereditary breast cancer: shared communication and care. J Clin Oncol (2003) 0.75
The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy. Can J Gastroenterol (2010) 0.75
Isolated metastasis to the cerebellopontine angle secondary to breast cancer. Can J Surg (2009) 0.75
Letters to the Editor. Nurs Leadersh (Tor Ont) (2010) 0.75
Exercise and cancer: no pain, some gain? J Clin Oncol (2003) 0.75
Accrual strategies for cancer genetics research: blurred boundaries. J Clin Oncol (2010) 0.75
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Support Care Cancer (2014) 0.75
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial. Pharmacoeconomics (2011) 0.75
The effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors' Pharmacare beneficiaries. Pharmacotherapy (2004) 0.75
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Res Treat (2009) 0.75